Current stratification in type 2 diabetes treatment guidelines involves preferential prescribing of two major drug classes, sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA), to subgroups of people with or at high risk of cardiorenal disease [2]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.